Entrada Therapeutics (TRDA) to Release Earnings on Friday

Entrada Therapeutics (NASDAQ:TRDA) will be posting its quarterly earnings results on Friday, March 8th.

Entrada Therapeutics Stock Up 1.5 %

Shares of TRDA stock traded up $0.19 during trading on Thursday, hitting $12.58. The company had a trading volume of 69,769 shares, compared to its average volume of 79,795. The stock’s 50-day moving average is $14.57 and its two-hundred day moving average is $14.80. The stock has a market capitalization of $419.79 million, a price-to-earnings ratio of -16.55 and a beta of -0.52. Entrada Therapeutics has a 52 week low of $10.11 and a 52 week high of $18.44.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright decreased their price objective on shares of Entrada Therapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, November 27th. Oppenheimer assumed coverage on shares of Entrada Therapeutics in a research report on Friday, January 5th. They issued an “outperform” rating and a $22.00 price objective on the stock.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 10,206 shares of the stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $15.69, for a total transaction of $160,132.14. Following the transaction, the chief financial officer now directly owns 49,571 shares in the company, valued at $777,768.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 13,300 shares of company stock worth $207,689 over the last ninety days. Insiders own 7.58% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. purchased a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $27,000. Royal Bank of Canada purchased a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $34,000. Lazard Asset Management LLC purchased a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $36,000. Legal & General Group Plc purchased a new stake in shares of Entrada Therapeutics during the fourth quarter valued at approximately $40,000. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of Entrada Therapeutics during the third quarter valued at approximately $40,000. 77.59% of the stock is currently owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1.